Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China

Share this

Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China


  • The company launched Xerava in China with the first prescription issued at Huashan Hospital affiliated with Fudan University
  • Xerava, the world's first fluorocycline antibiotic for the treatment of infections caused by susceptible gram+, gram-, and anaerobic pathogens incl. MDR isolates. The therapy is currently approved for complicated intra-abdominal infections in the US, EU, GB, Singapore, mainland China & Hong Kong and is currently under review for cIAI in the Taiwan region
  • The company is expected to launch 3 additional innovative drugs in China over the next 2yrs. incl. Nefecon for adults with primary IgAN with an expected approval in China in H2’23

Ref: PRNewswire | Image: Everest medicines

Related News:- Everest Medicines Signed a MoU with Shanghai Pharma Subsidiary to Advance the Commercialization of Xerava (eravacycline) in Mainland China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions